3E Bioventures’ Post

View organization page for 3E Bioventures, graphic

481 followers

3E Bioventures portfolio company Biosion recently shared the results from the ADAMANT study, a phase 2 proof-of-concept trial in AD subjects treated with Bosakitug, a high potency anti-TSLP mAb, in a podium presentation at the Revolutionizing Atopic Dermatitis conference in Chicago, IL. “Despite the limitations of the POC trial being open label, with a limited sample size of 21 subjects, the response profile is truly remarkable. We knew we had created an antibody with very high potency due to its long residency time on TSLP that could neutralize and clear TSLP from deep tissue spaces effectively. These promising clinical data give us a great deal of confidence to conduct a randomized and controlled phase 2 trial in moderate to severe AD as well as other indications,” said Biosion Chief Development Officer Hugh Davis, PhD.

View organization page for Biosion, graphic

734 followers

Biosion Today Presented Key Phase 2 POC Clinical Study Results for Bosakitug, an Anti-TSLP mAb, in Atopic Dermatitis Subjects at the Revolutionizing Atopic Dermatitis Conference. We are excited to see that Bosakitug's efficacy will lead to new therapeutic options for patients! #antibody #TSLP #AtopicDermatitis

Biosion Today Presented Key Phase 2 POC Clinical Study Results for Bosakitug, an Anti-TSLP mAb, in Atopic Dermatitis Subjects at the Revolutionizing Atopic Dermatitis Conference

Biosion Today Presented Key Phase 2 POC Clinical Study Results for Bosakitug, an Anti-TSLP mAb, in Atopic Dermatitis Subjects at the Revolutionizing Atopic Dermatitis Conference

biosion.com

To view or add a comment, sign in

Explore topics